Purpose This multicenter phase II trial evaluated lurbinectedin (PM01183), a selective inhibitor
of active transcription of protein-coding genes, in patients with metastatic breast cancer. A …

Inflammatory mediators present in the tumor milieu may promote cancer progression and are
considered promising targets of novel biological therapies. We previously reported that the …

There is widespread interest in macrophages as a therapeutic target in cancer. Here, we
demonstrate that trabectedin, a recently approved chemotherapeutic agent, induces rapid …

Resistance of human tumors to anticancer drugs is most often ascribed to gene mutations,
gene amplification, or epigenetic changes that influence the uptake, metabolism, or export of …

Cytotoxic nucleoside analogues and nucleobases were among the first chemotherapeutic
agents to be introduced for the medical treatment of cancer. This family of compounds has …

Trabectedin (ET-743) is a marine alkaloid isolated from the Caribbean tunicate Ecteinascidia
turbinata, with a chemical structure characterized by three fused tetrahydroisoquinoline …

We have defined the mechanism of action of lurbinectedin, a marine-derived drug exhibiting
a potent antitumor activity across several cancer cell lines and tumor xenografts. This drug, …

Factors that reduce the intracellular concentration of triphosphorylated cytarabine (ara‐CTP),
the active form of cytarabine (ara‐C), may induce chemoresistance in acute myeloid …

Trabectedin (Yondelis ® , ET-743) is a marine-derived natural product that was initially isolated
from the marine ascidian Ecteinascidia turbinata and is currently prepared synthetically. …

… Author links open overlay panel Carlos M. Galmarini a , Xavier Thomas b , Fabien Calvo
c , Philippe Rousselot d , Assia El Jafaari e , Emeline Cros a , Charles Dumontet a …